Locoregional Stomach Cancer
Gastric Adenocarcinoma
Male, 61
Patient Internal ID: 21798324
ICD-10 code
C16.8 Malignant Neoplasm of Overlapping Sites of Stomach
Diagnosis (Incl. Metastases/Stage) and Year
2015
In 2019-03 recurrence of Gastric Adenocarcinoma cTXN3bM1 G2-3 stage IV, HER2 (-). Metastases in the Abdomen and Left Lung.
Previous Treatment
Surgery (Gastrectomy), Surgery (Resection of the Esophagus and Small Bowel), Chemotherapy (Cisplatin and 5-Fluorouracil), Immunotherapy (Ramucirumab) and Chemotherapy (Paclitaxel), Chemotherapy (FOLFIRI scheme).
Prognosis and Survival Expectation
The prognosis remains poor, the median survival for patients with Metastatic Gastric Cancer reported ±14 months.
Treatment Provided
Allogeneic CIK (5 doses) over a period of 5 months.
Patient Survival/Condition and Year
Date of Review: 01/12/2023
The patient has survived for 19 months since the recurrence of the disease. It can be concluded that the addition of Immunotherapy, alongside Surgery and Chemotherapy, has extended patient survival by an estimate of around 5 months.
